Randomized controlled trial demonstrates improved liver fibrosis in NASH, supporting phase 3 clinical development.
In this phase 2b trial, treatment with pegozafermin led to improvements in fibrosis. These results support the advancement of pegozafermin into phase 3 development. (Funded by 89bio; ENLIVEN ClinicalTrials.gov number, NCT04929483.).
No takes yet. Share an insight, caveat, or question.
Loomba et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: